Shukra Pharmaceuticals Limited announced the opening of four new branch offices in key Indian cities — Mumbai, Gurgaon (NCR), Bangalore, and Kolkata — as part of its strategic growth initiative aimed at enhancing its market presence and operational reach.
In a regulatory filing to the stock exchanges dated July 9, 2025, the company said this expansion aligns with its vision of delivering quality pharmaceutical solutions across India and deepening engagement with institutional and healthcare stakeholders.
Key objectives of the new branches:
-
Explore and serve high-potential regional markets.
-
Participate more actively in tenders from Government, Semi-Government, and Private sector institutions.
-
Build closer partnerships with institutional clients, procurement agencies, and other healthcare stakeholders.
The company stated that these new offices are expected to catalyze enhanced business development, unlock growth avenues, improve operational agility, and create long-term value for shareholders.
Shukra Pharmaceuticals reaffirmed its commitment to transparency and assured stakeholders that all material developments will continue to be promptly communicated.
The disclosure was filed pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.